KML On Other Exchanges
Symbol
Exchange
Mumbai

kamron laboratories ltd (KML) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMRON LABORATORIES LTD (KML)
\

Related News

No related news articles were found.

kamron laboratories ltd (KML) Related Businessweek News

No Related Businessweek News Found

kamron laboratories ltd (KML) Details

Kamron Laboratories, Ltd. manufactures and markets pharmaceutical formulations in dosage forms, such as tablets, capsules, liquid orals, dry syrups, eye drops, and injections. The company’s products include proteolytic, anti-emetic, gastro intestinal, antibiotics, anti-cough anti-cold, digestive enzyme, nutritional, anti-malarial, anti-gout, analgesic anti inflammatory, anti-pyeric, calcium supplements, anti-spasmodic, haematinic, haemostatic, and others. It also offers educational products for medical education. In addition, the company engages in research and development activities, such as taste masking, development of sustained release products, aqueous coating and aromatic coating, and product stability. It has manufacturing facilities at Rakanpur, India. The company was founded in 1990 and is based in Gandhinagar, India.

Founded in 1990

kamron laboratories ltd (KML) Top Compensated Officers

Chief Executive & Executive Director
Total Annual Compensation: 639.1K
MD, Compliance Officer & Executive Director
Total Annual Compensation: 1.9M
CFO & Executive Director
Total Annual Compensation: 326.7K
Compensation as of Fiscal Year 2018.
kamron laboratories ltd
Kamron Laboratories Ltd to Report Fiscal Year 2019 Results on May 30, 2019

Kamron Laboratories Ltd announced that they will report fiscal year 2019 results on May 30, 2019

Kamron Laboratories Ltd, Board Meeting, May 30, 2019

Kamron Laboratories Ltd, Board Meeting, May 30, 2019. Agenda: To consider and approve the Standalone Audited Financial Results of the company for the Financial Year 2018-19 ended on 31st March, 2019.

Kamron Laboratories Ltd Appoints Bhavasthi R. Mehta as Company Secretary and Compliance Officer

Kamron Laboratories Ltd. has appointed Ms. Bhavasthi R. Mehta as a Company Secretary and Compliance Officer, effective February 14, 2019. Henceforth, Mr. Kamlesh J. Laskari, is not the Compliance officer of the Company.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

KML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KML.
View Industry Companies
 

Industry Analysis

KML

Industry Average

Valuation KML Industry Range
No financial data is available for KML.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAMRON LABORATORIES LTD, please visit www.kamronlabs.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.